Anti-IL17A, Ixekizumab, for treatment-resistant chronic venous leg ulcers: A phase II randomized, double-blind, placebo-controlled pilot trial
J Eur Acad Dermatol Venereol
.
2023 Mar 13.
doi: 10.1111/jdv.19041.
Online ahead of print.
Authors
C Cox
1
2
3
,
K Fry
1
,
Y Sivakumaran
4
,
L Spelman
3
,
K Khosrotehrani
1
2
3
Affiliations
1
The University of Queensland, Frazer Institute, Dermatology Research Centre, Experimental Dermatology Group, Brisbane, Queensland, Australia.
2
Department of Dermatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
3
Queensland Institute of Dermatology, Brisbane, Queensland, Australia.
4
Department of Vascular Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
PMID:
36914411
DOI:
10.1111/jdv.19041
No abstract available
Publication types
Letter
Grants and funding
Eli Lilly and Company
National Health and Medical Research Council